22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.
22 January 2026
21 January 2026
19 January 2026
16 January 2026
Latest Features
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Latest Conference Videos
Americas
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
Europe
Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection.
Biotechnology
Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
More News
16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.
15 January 2026 The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.
15 January 2026 A court has blocked the patent owner's latest attempt to stop a generic rival as it weighs the right way to challenge a new product.
15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.
14 January 2026 A high-profile departure from the USPTO sees a senior appellate expert move into private practice as demand increases in the firm's life sciences IP practice.
14 January 2026 The US firm has recruited a European patent attorney with three decades of experience to build its patent prosecution offering across the continent.
13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox